-
公开(公告)号：US20240299383A1
公开(公告)日：2024-09-12
申请号：US18205628
申请日：2023-06-05
发明人： Pan LI , Limin JIA , Zhiyong QIN , Zhaoyang WANG
IPC分类号： A61K31/506 , A61P37/04 , C07K16/28
CPC分类号： A61K31/506 , A61P37/04 , C07K16/2818 , C07K16/2827
摘要： The present invention discloses the inhibitory effect of azvudine as an immunomodulator on mice bearing CT-26 tumor. It is found that azvudine has no significant anti-tumor effect on immunodeficient B-NDG mice bearing CT-26 tumor, yet has an antitumor effect on BALB/c mice with normal immunity bearing CT-26 tumor model. The present invention further studies the combined effect of azvudine and PD-1 antibody, and finds that compared with a single drug, the combined administration has a synergistic anti-tumor effect.
-
公开(公告)号：US20240293438A1
公开(公告)日：2024-09-05
申请号：US18200000
申请日：2023-05-22
发明人： Pan LI , Limin JIA , Zhiyong QIN , Zhaoyang WANG
IPC分类号： A61K31/7068 , A61K31/337 , A61K31/655 , A61K31/675 , A61K39/395 , A61P35/00 , A61P35/02
CPC分类号： A61K31/7068 , A61K31/337 , A61K31/655 , A61K31/675 , A61K39/3955 , A61P35/00 , A61P35/02
摘要： The present invention discloses a pharmaceutical composition comprising azvudine and a chemotherapeutic agent. The pharmaceutical composition of the present invention shows a good synergistic effect in antitumor, and can reduce the dosage of chemotherapeutic agent, and improve the therapeutic effect and safety, thereby achieving the goal of prolonging the survival of patients.
-
搜索结果
2 条记录 (耗时 0.012 秒)
